Drug Database
HY

hyaluronic acid (Hyalart / HA, Fidia / Hyalgan)

✓ Approved

Shire · CD44

What is hyaluronic acid?

hyaluronic acid is a therapeutic agent developed by Shire. It is approved for therapeutic indications via injectable (others) or intraarticular injection or oral (po).

Drug Profile

Brand NamesHyalart, HA, Fidia, Hyalgan
CompanyShire
Molecular TargetCD44
RouteInjectable (Others), Intraarticular Injection, Oral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

hyaluronic acid acts on 1 molecular target:

CD44CD44 molecule (IN blood group) (MIC4, ECMR-III)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

hyaluronic acid is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Musculoskeletal and connective tissue disordersOsteoarthritis✓ Approved

Related Research Articles

PubMedBMC oral health2026-11-11

Histological and histomorphometric effects of hyaluronic acid with or without xenograft on rat extraction socket healing.

Habib Aliaa A AA, Salem Eman M EM

Alveolar bone loss following tooth extraction remains a major clinical concern that may compromise future implant placement and prosthetic rehabilitation. Hyaluronic acid (HA), a natural component of the extracellular matrix, exhibits anti-inflammatory, angiogenic, and osteogenic properties that may enhance post-extraction healing. This experimental study evaluated the effect of HA, used alone or combined with a xenograft, on bone regeneration in extraction sockets. Twenty adult female Sprague-Dawley rats were included. Two animals served as untreated baseline histological references, while the remaining eighteen rats underwent mandibular first molar extraction and were randomly allocated into three groups (n = 6/group): extraction only (control), HA application, and HA combined with xenograft. Each group was further evaluated at 2, 4, and 6 weeks post-extraction, with two animals assessed at each healing interval. Histological evaluation was performed using hematoxylin and eosin (H&E) and Masson's trichrome staining. Histomorphometric analysis quantified the percentage of newly formed bone area within standardized regions of interest using calibrated ImageJ software. Differences among treatment groups were analyzed separately at each healing interval using one-way ANOVA or the Kruskal-Wallis test, as appropriate, followed by appropriate post-hoc multiple comparisons. Statistical significance was set at p < 0.05. Both HA-treated groups demonstrated significantly greater bone formation compared with extraction alone at all healing intervals (p < 0.001). Histological assessment revealed reduced inflammatory infiltrate and more organized trabecular architecture in HA-treated sockets. Masson's trichrome staining demonstrated increased collagen deposition and matrix organization, particularly in the HA + xenograft group. Although the combination therapy demonstrated numerically higher bone area values throughout the healing period, no statistically significant difference was observed between HA alone and HA combined with xenograft (p > 0.05). Within the limitations of this exploratory pilot animal study, HA significantly enhanced extraction socket healing by promoting new bone formation, improving trabecular organization, and increasing collagen deposition compared with spontaneous healing. The addition of xenograft resulted in slightly higher histological and histomorphometric values; however, it did not result in statistically superior bone formation compared with HA alone within the experimental timeframe. These findings suggest that HA may represent a promising adjunctive biomaterial for alveolar ridge preservation. Nevertheless, larger preclinical studies and well-designed randomized clinical trials are required to validate these findings and determine their clinical applicability. The adjunctive application of hyaluronic acid (HA), with or without bone substitute materials, may enhance post-extraction bone quality and accelerate healing dynamics. This could support more predictable ridge preservation outcomes and potentially facilitate early implant placement by improving the quantity and quality of newly formed bone. Therefore, HA may represent a clinically relevant biomaterial in contemporary alveolar ridge preservation protocols.

PubMedPlastic and reconstructive surgery. Global open2026-11-11

The Aesthetic Smile Point for East Asians: A Novel Midfacial Injection Technique.

She Yuhong Y, Liao Yong Y, Ni Yishuang Y, Zhao Liangsen L

This study introduced an innovative morphological subclassification system of the infraorbital region for East Asian populations and proposes a novel injection technique centered on the "aesthetic smile point." Through static and dynamic assessments, this approach identifies subtype structural features and aesthetic concerns, which guide the precise application of high-viscosity, high-elasticity hyaluronic acid fillers via sharp-needle supraperiosteal injection. The technique addresses the anatomical characteristics of East Asians, such as a flatter midface and medially projected zygomatic apex, by restoring ideal contour balance and enhancing natural facial expressiveness in static and smiling states. The method improves midfacial harmony while reducing risks associated with overfilling and soft-tissue displacement. This framework offers a personalized, anatomy-based aesthetic strategy and holds promise for advancing midface rejuvenation practices in East Asian patients.

PubMedJournal of agricultural and food chemistry2026-11-11

Discovery of Novel Endolytic Hyaluronate Lyases Belonging to a New Subfamily of GH56 and Enhancement of Catalytic Activity through Catalytic Cleft Engineering.

Yu Xiangfan X, Jing Yiwen Y, Liu Lei L, Ma Zhenyu Z et al.

Hyaluronate lyases have been widely used to degrade hyaluronic acid (HA) and prepare HA oligosaccharides. To date, no hyaluronate lyase has been reported in glycoside hydrolase family 56 (GH56). Herein, SpskHL from Sporothrix schenckii 1099-18 was first identified as a GH56 endolytic hyaluronate lyase, and then its four homologues were discovered. These five microbial GH56 enzymes cleaved HA, yielding unsaturated HA oligosaccharides with ΔHA2 as the end product, forming a new GH56 subfamily of endolytic hyaluronate lyase. Through alanine-scanning mutagenesis of 15 residues in the catalytic cleft of SpskHL and combining three positive mutations, triple-site mutant SpskHLM3 (Y120A/N125A/H189A) increased activity by 126%. Grafting of the triple-site mutation onto four other hyaluronate lyases increased their activities by 74%-155%. Molecular dynamics simulations suggested that all five triple-site mutants had an expanded catalytic cleft, a larger cavity near the catalytic residue E, and a shorter catalytic OE2-O4 distance, which might contribute to their enhanced activities.

PubMedAdvanced functional materials2026-11-11

Dynamic Matrix Stiffening Reprograms Endothelial Angiogenic Remodeling via α2-Integrin Mechanotransduction.

Amelung Connor D CD, Tang Katherine K, Ripsky Sydney S, Warren Emily C EC et al.

Progressive stiffening of the extracellular matrix (ECM) is a hallmark of vascular aging and fibrosis. Stiffening the ECM disrupts endothelial adherens junctions and barrier function, but whether endothelial cells impact pericellular ECM, which in turn affects endothelial cell fate, remains unclear. Here, we use a phototunable collagen-hyaluronic acid hydrogel to impose in situ stiffening around endothelial colony-forming cells (ECFCs). In compliant matrices, ECFCs realigned collagen fibers, generated pericellular stiffening, and deposited nascent protein in spatial register with reorganized collagen. Dynamic stiffening disrupted this local feedback, with collagen alignment and pericellular stiffening suppressed despite unchanged collagen density, while nascent protein deposition increased but became uncoupled from constructive remodeling. Transcriptomic profiling revealed a shift from angiogenic, matrix-constructive programs toward stress-adaptive states. We identify α2-integrin as a key regulator of endothelial biosynthesis and collagen organization under dynamic stiffening. Inhibition of α2-integrin abolished stiffness-induced nascent protein deposition and weakened endothelial adhesion to collagen. Together, these findings establish α2-integrin-dependent mechanotransduction as a checkpoint linking dynamic ECM stiffening to suppression of endothelial pericellular remodeling, with implications for impaired vascular regeneration in aging and fibrosis.

PubMedCell death & disease2026-11-11

MASP1‑METTL3‑HAS2 axis aggravates liver fibrosis through HMW‑HA‑mediated senescence inhibition and LMW‑HA‑induced activation of hepatic stellate cells.

Liu Xianzhi X, Wang Peng P, Zeng Wei W, Liu Huajie H et al.

The hepatic microenvironment undergoes dynamic remodelling in advanced liver fibrosis. Hyaluronic acid (HA), a key component of this fibrotic microenvironment, plays a key role in disease progression. While cellular senescence is one of the fates that activated HSCs undergo and is associated with fibrosis resolution, the relationship between HA and HSC senescence in advanced liver fibrosis remains unclear. This study aimed to elucidate the specific mechanisms by which HA regulates HSC senescence. Here, intrahepatic HSC transplantation confirmed that an advanced fibrotic microenvironment inhibited HSC senescence and led to its sustained activation. Mechanistically, low-molecular-weight (LMW) HA promotes HSC activation via the CD44-p38-ATF2 axis, while HMW-HA simultaneously inhibits HSC senescence through the TLR4-SerpinE1 axis. Furthermore, HA synthesis is mediated by MASP1. MASP1 enhances the m6A methylation of HAS2 via METTL3, leading to increased HAS2 mRNA levels and consequently elevated HMW-HA synthesis, and HYAL2 mediates the conversion of HMW‑HA to LMW‑HA. Targeted knockdown of MASP1 in the liver reversed HA metabolism, subsequently promoting HSC senescence and alleviating liver fibrosis. Therefore, targeting HA metabolism to induce HSC senescence for activated HSC removal may represent a novel therapeutic strategy for liver fibrosis.

PubMedHistology and histopathology2026-11-11

Glycyrrhetinic acid alleviates LPS-induced acute lung injury and is associated with modulation of Keap1-Nrf2 signaling and ferroptosis.

Zheng Xiaona X, Zhao Liang L, Ye Ming M, Guo Qingwei Q et al.

Glycyrrhetinic acid, a substance extracted from licorice, has several pharmacological activities, such as anti-inflammatory and antioxidant effects and antiviral properties. Acute lung injury (ALI) represents a significant contributor to morbidity and mortality associated with respiratory disorders, marked by the presence of lung edema, interstitial neutrophilic infiltration, and dysfunction of intravascular and endothelial barriers, ultimately leading to respiratory failure. The present study aimed to investigate the effects of glycyrrhetinic acid on LPS-induced ALI. Glycyrrhetinic acid pretreatment significantly attenuated LPS-induced pulmonary edema, inflammatory cell infiltration, and alveolar wall thickening, while reducing proinflammatory cytokines (TNF-α, IL-1β) in BALF and serum. The transcriptomics analysis predicted that the ferroptosis pathways might be involved in the underlying mechanism of glycyrrhetinic acid against ALI, with validation experiments demonstrating glycyrrhetinic acid-mediated restoration of ferroptosis markers. Mechanistically, glycyrrhetinic acid suppressed Keap1 expression and activated Nrf2, enhancing antioxidant responses and inhibiting lipid peroxidation. These findings suggest that glycyrrhetinic acid may modulate inflammation and ferroptosis, with Keap1-Nrf2 signaling potentially contributing to its protective effects. The study suggests that targeting ferroptosis may represent a potential strategy for ALI management, with glycyrrhetinic acid emerging as a promising pharmacological candidate.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about hyaluronic acid